CHMP Backs First Anti-CGRP in Europe for Migraine

If approved, rimegepant would be the first CGRP receptor antagonist available in Europe and the only migraine medication approved for both acute and preventive treatment in adults.
International Approvals

source https://www.medscape.com/viewarticle/969451?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors